1.
Product Overview
2.
Research Methodology
3.
Executive Summary
4.
Impact of COVID-19 on Global Radiotheranostics Market
5.
Voice of Customer
5.1. Radiotheranostics
Awareness
5.2. Cancer Prevalence,
By Gender
5.3. Cancer Prevalence,
By Age Group
5.4. Cancer Prevalence,
Region
5.5. Benefits of Using
Radiotheranostics
6.
Clinical Trial Analysis
7.
Patent Analysis
8. Global Radiotheranostics
Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
8.2.2. By Application (Oncology v/s Non-Oncology)
8.2.2.1.
Oncology Applications
(Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple
Myeloma and Lymphoma, Others)
8.2.2.2.
Non-Oncology Applications
(Joint Infections, Arthritis, Bone Pain, Others)
8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
8.2.4. By Region
8.2.5. By Company (2021)
8.3.
Product Market Map
9. North America Radiotheranostics
Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
9.2.2. By Application (Oncology v/s Non-Oncology)
9.2.2.1.
Oncology Applications (Thyroid
Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and
Lymphoma, Others)
9.2.2.2.
Non-Oncology Applications
(Joint Infections, Arthritis, Bone Pain, Others)
9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
9.2.4. By Country
9.3.
North America: Country Analysis
9.3.1. United States Radiotheranostics
Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Radioisotope
9.3.1.2.2.
By Application
9.3.1.2.3.
By End User
9.3.2. Mexico Radiotheranostics
Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Radioisotope
9.3.2.2.2.
By Application
9.3.2.2.3.
By End User
9.3.3. Canada Radiotheranostics
Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Radioisotope
9.3.3.2.2.
By Application
9.3.3.2.3.
By End User
10. Europe Radiotheranostics
Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
10.2.2. By Application (Oncology v/s Non-Oncology)
10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer,
Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain,
Others)
10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
10.2.4. By Country
10.3.
Europe: Country Analysis
10.3.1. France Radiotheranostics
Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Radioisotope
10.3.1.2.2.
By Application
10.3.1.2.3.
By End User
10.3.2. Germany Radiotheranostics
Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Radioisotope
10.3.2.2.2.
By Application
10.3.2.2.3.
By End User
10.3.3. United Kingdom Radiotheranostics
Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Radioisotope
10.3.3.2.2.
By Application
10.3.3.2.3.
By End User
10.3.4. Italy Radiotheranostics
Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Radioisotope
10.3.4.2.2.
By Application
10.3.4.2.3.
By End User
10.3.5. Spain Radiotheranostics
Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1.
By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1.
By Radioisotope
10.3.5.2.2.
By Application
10.3.5.2.3.
By End User
11. Asia-Pacific Radiotheranostics
Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
11.2.2. By Application (Oncology v/s Non-Oncology)
11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer,
Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain,
Others)
11.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
11.2.4. By Country
11.3.
Asia-Pacific: Country Analysis
11.3.1. China Radiotheranostics
Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Radioisotope
11.3.1.2.2.
By Application
11.3.1.2.3.
By End User
11.3.2. India Radiotheranostics
Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Radioisotope
11.3.2.2.2.
By Application
11.3.2.2.3.
By End User
11.3.3. South Korea Radiotheranostics
Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Radioisotope
11.3.3.2.2.
By Application
11.3.3.2.3.
By End User
11.3.4. Japan Radiotheranostics
Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1.
By Radioisotope
11.3.4.2.2.
By Application
11.3.4.2.3.
By End User
11.3.5. Australia Radiotheranostics
Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1.
By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1.
By Radioisotope
11.3.5.2.2.
By Application
11.3.5.2.3.
By End User
12. South America Radiotheranostics
Market Outlook
12.1.
Market Size & Forecast
12.1.1. By Value
12.2.
Market Share & Forecast
12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
12.2.2. By Application (Oncology v/s Non-Oncology)
12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer,
Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain,
Others)
12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
12.2.4. By Country
12.3.
South America: Country Analysis
12.3.1. Brazil Radiotheranostics
Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1.
By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1.
By Radioisotope
12.3.1.2.2.
By Application
12.3.1.2.3.
By End User
12.3.2. Argentina Radiotheranostics
Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1.
By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1.
By Radioisotope
12.3.2.2.2.
By Application
12.3.2.2.3.
By End User
12.3.3. Colombia Radiotheranostics
Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1.
By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1.
By Radioisotope
12.3.3.2.2.
By Application
12.3.3.2.3.
By End User
13. Middle East and
Africa Radiotheranostics Market Outlook
13.1.
Market Size & Forecast
13.1.1. By Value
13.2.
Market Share & Forecast
13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F,
Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
13.2.2. By Application (Oncology v/s Non-Oncology)
13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer,
Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain,
Others)
13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology
Companies, Others)
13.2.4. By Country
13.3.
MEA: Country Analysis
13.3.1. South Africa Radiotheranostics
Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1.
By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1.
By Radioisotope
13.3.1.2.2.
By Application
13.3.1.2.3.
By End User
13.3.2. Saudi Arabia Radiotheranostics
Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1.
By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1.
By Radioisotope
13.3.2.2.2.
By Application
13.3.2.2.3.
By End User
13.3.3. UAE Radiotheranostics
Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1.
By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1.
By Radioisotope
13.3.3.2.2.
By Application
13.3.3.2.3.
By End User
14.
Market Dynamics
14.1.
Drivers
14.2.
Challenges
15.
Market Trends & Developments
16.
SWOT Analysis: Global Radiotheranostics Market
17.
Competitive Landscape (Inclusive of SWOT Analysis of
Players Profiled)
17.1.
TransCode Therapeutics, Inc.
17.2.
Curium SAS
17.3.
GE Healthcare Inc.
17.4.
Bayer AG
17.5.
Lantheus Medical Imaging, Inc.
17.6.
Novartis AG
17.7.
Spectrum Pharmaceuticals, Inc.
17.8.
Ipsen S.A.
17.9.
Actinium Pharmaceuticals, Inc. (ATNM)
17.10.
Nordic Nanovector ASA
17.11.
Y-mAbs Therapeutics, Inc.
17.12.
Sofie Biosciences, Inc.
17.13.
Terumo Corporation
17.14.
Sirtex Medical Limited
17.15.
Boston Scientific Corporation
18.
Strategic Recommendations
(Note: The
companies list can be customized based on the client requirements.)